Month: June 2015

On Jan 26, shares of UnitedHealth Group Inc. UNH scaled an all-time new 52-week high of $124.11. […]

Netflix, Inc. NFLX recently unveiled its plans to launch its services in India. The initiative is a part of the company’s strategy to extend its global presence by 2016. […]

ConAgra Foods, Inc. CAG is scheduled to report fourth-quarter fiscal 2015 results before the opening bell on Jun 30, 2015. […]

France-based global telecommunications service provider, Orange SA ORAN recently received Jazztel Plc. shareholders' approval to acquire the latter. Jazztel is a leading provider of broadband services along with fixed-line and mobile phone services to enterprises and consumer markets in Spain […]

eBay Inc. ’s EBAY board has finally given its stamp of approval to PayPal’s spinoff as a separate public company. In September last year, eBay had announced that it will spin off its PayPal payments unit into a separate publicly-traded company as early as the second half of this year […]

When it comes to apparel, we are spoilt for choice. Yet, we buy only those that best suit our personality, without compromising on fashion, fabric, color, design or size. The same principle applies when picking a stock as we always prefer a well-tailored portfolio that promises higher returns. […]

On June 26, we issued an updated research report on paints and coatings maker Valspar VAL . Valspar’s profit rose in second-quarter fiscal 2015 (ended May 1, 2015), reported on May 27, on its cost-containment and productivity actions. Adjusted earnings beat the Zacks Consensus Estimate. […]

Novartis AG NVS announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx. FUTURE 2 evaluated the efficacy and safety of Cosentyx for the treatment of patients suffering from psoriatic arthritis. Novartis reported that FUTURE 2 met its primary endpoint at week 24 as subcutaneous doses of Cosentyx (300 mg and 150 mg) led to improvements that sustained over one year of treatment in the majority of patients. […]

Black Hills Corporation BKH announced that it has extended its unsecured revolving credit facility of $500 million. The amended facility can be increased to $750 million subject to specific conditions and has a five-year term expiring Jun 26, 2020. The extended credit facility will be used to fund various general corporate purposes like working capital needs and others. […]

On Jun 26, 2015, shares of Smith & Wesson Holding Corporation SWHC reached a new 52-week high of $17.04, finally closing at $16.80. The closing price reflects a gain of almost 77.4% so far this year. Smith & Wesson recently announced that its board of directors has approved a buyback of up to $50 million worth of shares that will remain active through Jun 23, 2017. […]

On Jun 26, we issued an updated research report on The Bank of New York Mellon Corporation BK . Shares of this N.Y.-based major regional bank have recorded a year-to-date return of 7.2%. […]

On Jun 29, Zacks Investment Research updated the research report on premier waste management firm Republic Services, Inc. RSG . Republic Services is the second largest domestic non-hazardous solid waste company in the U.S. […]

Transportation company JB Hunt Transport Services JBHT is set to join the S&P 500 index after market closes on Jun 30, 2015. J.B. Hunt will replace Integrys Energy Group TEG which will be acquired by the Milwaukee-based utility holding company Wisconsin Energy Corp. […]

Alexion Pharmaceuticals, Inc. ALXN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has rendered positive recommendations relating to the marketing authorization of Strensiq (asfotasealfa) and Kanuma (sebelipasealfa). Alexion is looking to get Strensiq approved as a long-term enzyme replacement therapy in patients suffering from pediatric-onset hypophosphatasia to treat the bone manifestations of the disease […]

Roche Holding AG ’s RHHBY Perjeta (in combination with Herceptin and chemotherapy) received positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP) as a neoadjuvant (pre-surgery) treatment of patients suffering from HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at a high risk of recurrence. Roche stated that the CHMP’s recommendation for Perjeta was the first of its kind in the neoadjuvant setting based on encouraging pathological complete response in a phase II study (NeoSphere) on the candidate. According to the World Health Organization and other sources, approximately 100,000 people in Europe are diagnosed with HER2-positive breast cancer each year […]

Biogen Inc. BIIB and partner Swedish Orphan Biovitrum (Sobi) announced that the European Medicines Agency (EMA) has accepted for review their marketing application for Alprolix. The companies are looking to get Alprolix approved for the treatment of hemophilia B […]

Regeneron Pharmaceuticals, Inc. REGN announced that Bayer’s BAYRY Japanese subsidiary, Bayer Yakuhin, Ltd. gained approval for Eylea for yet another indication in Japan. […]